

INFORMATION TO USERS

This reproduction was made from a copy of a document sent to us for microfilming. While the most advanced technology has been used to photograph and reproduce this document, the quality of the reproduction is heavily dependent upon the quality of the material submitted.

The following explanation of techniques is provided to help clarify markings or notations which may appear on this reproduction.

1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting through an image and duplicating adjacent pages to assure complete continuity.
2. When an image on the film is obliterated with a round black mark, it is an indication of either blurred copy because of movement during exposure, duplicate copy, or copyrighted materials that should not have been filmed. For blurred pages, a good image of the page can be found in the adjacent frame. If copyrighted materials were deleted, a target note will appear listing the pages in the adjacent frame.
3. When a map, drawing or chart, etc., is part of the material being photographed, a definite method of "sectioning" the material has been followed. It is customary to begin filming at the upper left hand corner of a large sheet and to continue from left to right in equal sections with small overlaps. If necessary, sectioning is continued again—beginning below the first row and continuing on until complete.
4. For illustrations that cannot be satisfactorily reproduced by xerographic means, photographic prints can be purchased at additional cost and inserted into your xerographic copy. These prints are available upon request from the Dissertations Customer Services Department.
5. Some pages in any document may have indistinct print. In all cases the best available copy has been filmed.

**University
Microfilms
International**

300 N. Zeeb Road
Ann Arbor, MI 48106

8508741

Uyar, Ruhi

**REGULATION OF RAT MEGAKARYOCYTE DEVELOPMENT IN PLASMA CLOT
CULTURE SYSTEM**

City University of New York

PH.D. 1985

**University
Microfilms
International** 300 N. Zeeb Road, Ann Arbor, MI 48106

REGULATION OF RAT MEGAKARYOCYTE DEVELOPMENT
IN PLASMA CLOT CULTURE SYSTEM

by

RUHI UYAR

A dissertation submitted to the Graduate
Faculty in Biology in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy, The City University
of New York

1985

This manuscript has been read and accepted for the Graduate Faculty in Biology in satisfaction of the dissertation requirement for the degree of Doctor of Philosophy.

Nov 30, 1984
date

George W. Cooper
Chairman of Examining Committee

JAN. 4. 1985
date

John C. Quinn
Executive Officer

Burton Dornfest
Burton Dornfest, SUNY, Downstate Med. Cent.

Max Hamburg
Max Hamburg, City College

Harvey L. Ozer
Harvey L. Ozer, Hunter College

James H. Wyche
James Wyche, Hunter College

Ralph C. Zuzolo
Ralph Zuzolo, City College

Supervisory Committee

ACKNOWLEDGEMENTS

I am extremely grateful to Dr. G.W. Cooper for his advice, assistance and support in making this work possible.

I would like to thank Doctors B.S. Dornfest, M. Hamburg, H.L. Ozer, J.H. Wyche and R.C. Zuzolo. I also wish to thank the technical and secretarial staff of Biology Department, The City College of the City University of New York. In addition, the help of Elvir Dincer and Jammie Lloyd is greatly appreciated.

Finally, I am very grateful to my wife, Fatma, for being there during those times.

This research was supported by grant number 6-63184 from the PSU-CUNY Research Award Program of the City University of New York, by the Biology Department of The City College of the City University of New York, and by the Turkish Ministry of Education.

TABLE of CONTENTS

	pages
1. Acknowledgements	iii
2. Table of Contents	iv
3. List of Tables	v
4. List of Figures	vi-vii
5. Introduction	1-6
6. Materials and Methods	7-12
7. Results	13-20
8. Discussion	21-30
9. Summary	31-32
10. Appendix	33-65
11. Bibliography	66-75.

LIST of TABLES

1. Culture conditions for megakaryocyte growth.
2. The effect of platelet extracts (PE₁ and PE₂) on WBC colonies/culture.
3. The effect of platelet extracts (PE₃ and PE₃) on WBC colonies/culture.
4. The effect of different concentrations of PDGF on the mean diameter of AChE+ cells.

LIST of FIGURES

1. The effects of conditioned media on rat bone marrow cell growth.
2. The effects of different serum concentrations on AChE+ cell growth.
3. The effects of different serum concentrations on the growth of AChE+ cell colonies.
4. The comparison of effects of 20% horse serum and 10% rat serum on AChE+ cell growth.
5. The effects of different plasma concentrations on the growth of AChE+ cells.
6. The effects of different plasma concentrations on the growth of AChE+ cell colonies.
7. The effects of different plasma concentrations on the growth of WBC colonies.
8. The comparison of the effects of 10% serum and 10% plasma on AChE+ cell growth.
9. The effects of PE₁ and PE₂ on the growth of AChE+ cells.
10. The effects of PE₃ and PE₄ on the growth of AChE+ cells.
11. The comparison of the effects of different doses of PE on the growth of AChE+ cells.
12. The effects of 6 ng and 12 ng PDGF/ml on the

growth of AChE+ cells.

13. The comparison of the effects of 6 ng PDGF/ml and PE₂ on the growth of AChE+ cells.

14. The effects of PE₁ and PE₂ on the mean diameters of AChE+ cells.

15. The effects of PE₃ and PE₄ on the mean diameters of AChE+ cells.

INTRODUCTION

Each type of blood cell is replenished from hemato-
poietic stem cells located in the red bone marrow and
the spleen. This pluripotential stem cell compartment re-
mains stable in size under homeostatic conditions. When
the specific stimulator is provided, the stem cell will
become committed to megakaryocytopoiesis, but does not
immediately differentiate further or enter into active
proliferation (1). The committed precursor cells (colony
forming unit-megakaryocytes:CFU-M) are low in number,
about $1/10^4$ bone marrow cells, and slow cycling, 7-20%
are in DNA synthesis. Thereafter, the CFU-M appear to
undergo cellular proliferation and initiate nuclear rep-
lication without cell division before becoming recogniz-
able as megakaryocytes. Therefore, megakaryocytes are
polyploid, and, in the normal steady state they have 4,
8, and 16 times the normal diploid amount of DNA (2).
The size of megakaryocytes is proportional to ploidy,
but the relationship of size and ploidy of a megakaryo-
cyte to the number and the size of platelets it pro-
duces is not clear (3). Each cell normally produces a
few thousand enucleate platelets by precisely controll-
ed cytoplasmic fragmentations (4).

A major reason for studying megakaryocytopoiesis
is to understand and to quantitate platelet production.

However, the nature of these mechanisms and their consequences are poorly understood. The megakaryocytes are of interest to cell biologists and physiologists because of these unusual mechanisms, and to experimental pathologists and hematologists for their perspective on platelet contributions to hemorrhagic and thrombotic diseases. Furthermore, there is increasing evidence of the importance of blood platelets in the pathogenesis of atherosclerosis. The participation of platelets in immune processes and in the spread of cancer is also receiving attention. Finally, a lively and productive interest in platelet pharmacology has developed, in the hope of conceiving and developing new drugs for the control of thrombosis and atherosclerosis.

In vivo studies of megakaryocytopoiesis in humans have been limited because of ethical questions related to a lack of suitable subjects for experimentations, and the limited nature of experiments that could be done on these subjects. The development of in vitro culture systems provided an alternative method for characterizing regulatory activities and analyzing the role of these activities in the proliferation of megakaryocytes. In the last nine years, both agar (5,6,7,8) and plasma clot (9,10,11,12) culture systems have been applied to the study of the biology of megakaryocytes. The application of in vitro culture systems to assay for CFU-M from mouse (10) and human (11) bone marrow have renewed

interest in the cellular and humoral mechanisms that regulate megakaryocytopoiesis and thrombopoiesis. These cloning assays have also allowed megakaryocytes to be isolated (13) and their precursor cells to be studied and monitored.

Although the application of semi-solid culture techniques to the study of megakaryocytes is not relatively new, culture conditions must still be further defined. This is especially in light of stimulation of megakaryocytic precursor cells by prerequisite conditioned media, the average small colony size, and the presence of numerous single megakaryocytes among the colonies (14). It still remains to be determined whether these properties reflect the limited proliferative capacity of megakaryocyte progenitors in vivo, or are caused by less than optimal culture conditions. However, a comparison of the different techniques (Table 1) used to culture CFU-M clearly presented numerous, potentially important differences (20). These differences include the use of different culture media, different conditioned media or other stimulators, and different sources and concentrations of serum. Some of the uncertainties may be due to the uncharacterized components used and the complexity of current culture systems. The first part of this project approached this question of defining culture conditions by

developing a simpler plasma clot culture system. A different species, namely the rat, Ratus norvegicus, was used as a donor of bone marrow cells, spleen cells conditioned medium, citrated plasma and serum.

Changes in marrow megakaryocytes which occur with experimentally induced thrombocytosis indicate that platelet production is subject to negative feedback regulation (21, 22, 23). Recent studies have shown that there are at least two levels of regulation of megakaryocytopoiesis and platelet production (24, 25, 26). At the first level, a compartment of precursor cells was shown to proliferate in response to cell derived products promoted by mitogen stimulation, recognition of decreased marrow megakaryocytes, and/or modulation of the concentration of cholinergic agonists (27). At the second level, however, ploidy amplification in the differentiated megakaryocyte compartment may be promoted by acute changes in platelet demand. In spite of some uncertainties, it is clear that a deficiency of circulating platelets is associated with the stimulation of megakaryocytopoiesis (28) and an excess with its suppression (29). There is some suggestive evidence which supports the idea that ploidy amplification is mediated by the hormone thrombopoietin (30, 31). Thus, separate factors independently influence proliferation and maturation events, but it is not known whether only

a single factor is involved at each level. Therefore, it is possible that platelets themselves and/or their products may well be involved in controlling production and release of platelets from megakaryocytes (32, 33).

A number of investigators have shown that extracts of erythrocytes, granulocytes and lymphocytes have some specific effects on the maturation of these cells (34,35, 36). These extracts have frequently been called "chalones" and their specificity of action for cells of their own kind has been demonstrated. The extracts of these cell types do not appear to affect the expansion and differentiation of their respective progenitor cells, rather these components modulate the late events of the cell division and maturation stages. Similarly, platelet extracts might influence the terminal stages of megakaryocyte maturation, including endomitosis, cell size, and cytoplasmic maturation. In support of this hypothesis, platelet extracts did not appear to affect the number of CFU-M in vivo, or their growth in vitro (37).

Human platelets contain a growth promoting factor called platelet-derived growth factor (PDGF) that stimulates the growth of smooth muscle cells, glial cells and fibroblasts as well as avian, monkey and murine fibroblastic cell lines (38). PDGF is a cationic polypeptide that is synthesized by megakaryocytes and stored in the

alpha granules of platelets (39). It has been purified and characterized as a 28,000-30,000 dalton polypeptide that is heat stable (40). Although PDGF has been extensively studied in investigations concerning inflammatory and repair processes at the site of blood vessel injury, PDGF might also play an important role in the genesis of atherosclerosis. It is a major mitogenic protein in the serum for cells of mesenchymal origin (41).

In the second part of this project, the effects of platelet extract and human PDGF on rat bone marrow cells in plasma clot cultures were investigated. Changes in the numbers of AChE+ cells, the mean diameters of these cells, and white blood cells (WBC) colony numbers were studied. Different concentrations of platelet extracts increased the detectability and the mean diameters of AChE+ cells, but decreased the number of WBC colonies in one series of experiments. PDGF also caused an increase in the cell number, but it had no effect on the cell size.

MATERIALS and METHODS

Bone marrow cells, spleen cells, plasma, serum and platelets were obtained from untreated Wistar rats. Bone marrow was flushed with Leibovitz medium (L-15, from Gibco, Grand Island, N.Y.) into plastic tubes from both femurs of 3-4 month-old female rats. Nucleated bone marrow cells were counted by a Coulter Counter. Blood was drawn into plastic syringes containing 3.8% (w:v) sodium citrate (1:9 citrate:whole blood) by cardiac puncture from 8-12 month-old male rats. The blood was centrifuged at 4 °C at 1100 x g for 15 min in an angle-head centrifuge to yield plasma. The same procedure was followed for collecting serum except that the anticoagulant was not used, and the blood was allowed to clot in the refrigerator. Both plasma and serum were filtered through 0.45 µm pore size Millipore filters after collection and stored at -70 °C until use.

A modification of the method of Goldberg et al (42) was used for the collection of platelets from similar rats that were lightly anesthetized with ether. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 500 x g for 4-5 min at room temperature. The remaining red blood cells (RBC) were resuspended in sterile isotonic saline to a total volume of 15 ml, and were

centrifuged at 500 x g for 3-4 min. This platelet suspension in saline was combined with the platelet-rich plasma and was sedimented at 1240 x g for 10 min. This yielded a platelet pellet containing visible RBC in the center of the pellet. The supernatant solution were decanted with a polypropylene plastic Pastur pipet and the platelets were removed from the tubes, leaving most of the RBC behind. The platelets were resuspended in saline in fresh plastic tubes. The platelet suspensions were centrifuged at 2200 x g for 12 min, the platelets were decanted as before, and resuspended in saline in order to remove the remaining RBC. The latter step was repeated four more times. The final platelet pellet, without visible RBC, was resuspended in sterile saline. Platelet numbers were determined by the use of both the Coulter Counter and the phase contrast microscope. The total number of platelets was determined from the platelet count and the volume of the final suspension. This suspension was then stored overnight at -20 °C. The platelets were disrupted by four cycles of freezing at -70 °C for 45 min, followed by thawing at 37 °C (43). The thawed suspension was finally sedimented at 3500 x g for 30 min, and the supernatant fraction was used as platelet extract. Calculated amounts of PE in saline were added to the cultures at the beginning of each incubation.

Pokeweed mitogen (Gibco)-stimulated rat spleen cells conditioned medium (RSCCM) was prepared by the method of Nakeff (14). The spleens of 2-4-month-old female rats were minced in a culture dish and homogenized in a plastic test tube with a 10 ml plastic syringe and a 22 G, 3.0 cm needle. Nucleated cells were counted and cultured in 35 mm culture dishes for two days. Each dish contained the following ingredients: (a) 60% L-15; (b) 10% bovine embryo extract diluted 1:4 (v/v) with L-15; (c) 10% rat serum; (d) 10% pokeweed mitogen (1/300 final dilution); (e) 10% rat spleen cells (2×10^6 /ml) in L-15. The medium was collected and filtered through 0.22 μ m Millipore filters. Each conditioned media was tested for potency before its final use and then stored at -70°C for no longer than two months.

Receptor grade PDGF (Seragen, Inc., Boston, MA) isolated in pure form (95%) from human platelets was dissolved in 1.0 M acetic acid. Sterile filtered tissue culture grade sodium bicarbonate (Gibco) was added to all the cultures, in order to readjust the pH to 7.4 following the addition of acetic acid.

Ten percent citrated rat plasma was used in this study instead of the commonly used 10% citrated bovine plasma. These two plasmas were not compared experimentally.

A modification of a previously described method (9) was used to culture the bone marrow cells in 96-well round bottom plastic plates. Each 0.3 ml plasma clot culture contained the following percentages (v/v) of these ingredients: (1) 40% L-15; (2) 10% RSCCM; (3) 10% bovine embryo extract diluted 1:4 with L-15; (4) 10% rat bone marrow cells (10^6 /ml in L-15); (5) Either 20% horse serum (Gibco), 10%, 15% or 20% rat serum, or 10%, 15% or 20% rat plasma; (6) 5% or 10% saline when 15% or 10% plasma or serum, respectively, were used, or either 10% PE or 10% PDGF; (7) 10% rat plasma (in addition to the 10% to 20% plasma or serum).

The bone marrow cells were cultured for one hour to 9 days in an incubator at 37 °C in an atmosphere of 6% CO₂ in air and 97% relative humidity. At daily intervals, plasma clots were rimmed and transferred to glass slides. The clots were partially dehydrated by placing pieces of filter papers on their surfaces. A second piece of filter paper was applied to the first filter paper and allowed to remain long enough for this paper to become moist. With the aid of forceps, the top piece of filter paper was removed and 3 drops of 5% glutaraldehyde (in 0.01 M phosphate buffer, pH 7.0) were placed on the remaining filter paper with a pipet. The first paper with glutaraldehyde was left in place for 10 min and

then gently pressed with a thumb. After removing the remaining filter paper, the slides with fixed plasma clots were rinsed in 0.1 M sodium phosphate buffer, pH 6.0 for one min and air dried with a blower. The fixed and dried clots were stained by the use of the "direct-coloring" thiocholine method for acetylcholinesterase activity (44). For staining, the clots were incubated for 3-4 hours at room temperature in a solution containing: (a) 600 mg of acetylthiocholine iodide, (b) 90 ml of 0.1 M sodium phosphate, pH 6.0, (c) 6 ml of 0.1 M sodium citrate, (d) 12 ml of 30 mM copper sulphate, (e) 12 ml of distilled water, and (f) 12 ml of 5 mM potassium ferricyanide. Following a one min rinse in 0.1 M sodium phosphate, postfixation in absolute methanol for 10 min, and 50% methanol for 30 sec, the cells were counterstained in Harris' hematoxyline for 4-6 min, and then rinsed twice in tap water. The slides were then blued by dipping in a 2% ammonium hydroxide solution, clarified in tap water and mounted.

It was recently hypothesized that the total number of megakaryocytic cells in plasma clots could be used to estimate the number of megakaryocyte colonies, and was a good index of the rate of megakaryocytopoiesis (15). Therefore, the number of AChE+ cells, rather than AChE+ cell colonies, was scored in some of these experiments. Otherwise, an AChE+ cell colony was defined as three or more cells in close proximity. Aggregates of

16 or more cells with horseshoe- or doughnut-shaped nuclei were considered to be a WBC colony.

The final preparations were examined under the light microscope at magnifications of 200X, 300X and 430X to determine the number of AChE+ cells, the number of AChE+ cell colonies and the number of WBC colonies. The measurement of AChE+ cell size was done by use of an ocular micrometer at magnifications of 300X and 430X. Two areas that were each the width of one microscope field in the middle of each clot were examined from the top to the bottom of the slide. All the megakaryocytic cells in these areas were measured. The average of the lengthwise diameter and the crosswise diameter was scored.

The Student t test was used for statistical significance.

RESULTS

In each experiment that produced conditioned medium, two sets of spleen cells were incubated with pokeweed mitogen at the same time under identical culture conditions. The conditioned media were then immediately tested for their ability to promote mitotic activity of rat bone marrow cells. Cultures treated with some preparations of the conditioned medium (RSCCM₃) showed a 72% greater number of megakaryocytic cells, scored as AChE+ cells/clot, than the controls at day 4 (Fig 1). This was highly significant ($P < 0.001$). Other preparations (RSCCM₂) showed about 41% greater mitotic activity than the isotonic saline controls ($P < 0.005$). However, a few preparations (RSCCM₁) showed no greater mitotic activity than the control groups, which showed 40% increase in cell numbers (Fig 1). Generally, rat bone marrow megakaryocytes formed colonies, matured fully, and produced cytoplasmic fragmentation when RSCCM was in the medium. Typical small megakaryocyte colonies with varying sizes could be seen as early as 2 to 3 days. Most colonies consisted of 3-6 cells, but at day 5 and later, loose colonies varied between 4 and more than 32 cells in number. Most of the colonies on days 2-4 were tight and small, containing about 8 cells, but they became loose

and larger on days 5-7. The number of single megakaryocytes in the cultures increased as the incubation time increased.

The effects of using 10%, 15% or 20% concentrations of rat serum were compared in Fig 2. The number of AChE+ cells counted was highest on day 4 in all experiments. When the number of AChE+ cells in the 10% rat serum group were compared to the 15% and 20% rat serum groups on day 4, the cultures containing 10% serum showed 17% ($P < 0.01$) and 28% ($P < 0.01$) more cell growth, respectively.

The number of AChE+ cell colonies was also determined when three concentrations of rat serum were used (Fig 3). The largest number of colonies was detected on day 4 for all concentrations of serum. When the maximum cell numbers (Fig 2) were divided by the maximum colony numbers (Fig 3) for all serum concentrations, 10, 11, and 12 were the mean cell numbers/colony for cultures containing 10%, 15% or 20% rat serum, respectively. However, the average number of cells in each colony on day 4 for all concentrations of serum ranged between 4 to 8, and increased further to 16 to 32 cells/colony on day 6. The difference between the actual and the calculated mean number of cells in the colonies emphasized the presence of single cells in the cultures. Tight co-

lonies were rarely seen, since most of the colonies were spread out.

Horse serum, widely used as a supplement in cell culture media, was compared to rat serum in another study (Fig 4). Ten percent rat serum caused 22% more cell growth than 20% horse serum ($P < 0.01$), as determined by the increase in AChE+ cell numbers on day 4. There were no noticeable differences in the appearance of these cells in any of these cultures. Since these results seemed conclusive, 10% rat serum was used in all future experiments that had serum. Furthermore, 10% rat serum replaced 20% horse serum in RSCCM production.

The effects of using 10%, 15% or 20% citrated rat plasma as a substitute for 10%, 15% or 20% rat serum were investigated. These three plasma concentrations were added in addition to the original 10% plasma that was routinely used in plasma clot cultures. Thus, the total amount of plasma in these cultures was 20%, 25% or 30%. Three waves of cell proliferation appeared on days 3, 6 and 9 (Fig 5). Maximum cell numbers were noted on day 3 for all three concentrations, and the increases in all numbers relative to day 0, were 75%, 65% and 40% respectively. There again was a gradual increase in the cell numbers, as the concentrations of rat plasma decreased. The differences between 10% and 15% plasma, and

10% and 20% plasma on day 3 were significant ($P < 0.02$ and $P < 0.01$, respectively). In general, the cells were smaller when plasma was substituted for serum, and cell shapes were oval to round. However, occasional elongated and irregular shapes were seen when serum was used. Sometimes a few AChE+ cells showed formation of pseudopods, and cytoplasmic budding with formation of platelets, but the number of such cells seem to be higher in the serum cultures.

A linear increase in the number of AChE+ cell colonies, with decreased concentrations of plasma was seen (Fig 6). Peaks were noted on days 4 and 8. The size of the colonies on day 9 was relatively larger than on previous days, but all the cells degenerated on days 8 and 9. The presence of single cells in these clots was a little higher than in the serum cultures, except on day 9, when the colonies consisted of more than 32 degenerated cells.

The number of WBC colonies in these cultures was also quantitated in order to compare the occurrence of WBC colonies with AChE+ cell colonies in the plasma studies (Fig 7). The only peak was on day 4 in all groups. This implied that the successive increases and decreases in numbers was unique to AChE+ cells and colonies, and occurred only in cultures that used plasma

as a supplement.

The effects on AChE+ cell proliferation of the addition of either 10% rat serum or 10% rat plasma, were compared (Fig 8). Maximum cell proliferation occurred on day 4, using 10% serum, and on day 3 when 10% plasma was added. The increase in the cell numbers from day 0 to day 4 when serum was added to the medium was 38% greater than the increase in cell numbers found from day 0 to day 3, when plasma was added.

A normal, 10-12 month-old male rat has approximately 900×10^6 platelets/ml of circulating blood. Therefore, it was readily possible to prepare PE from the following concentrations of platelets: 450×10^6 (PE₁), 675×10^6 (PE₂), 900×10^6 (PE₃) and 1800×10^6 (PE₄) platelets/ml isotonic saline. These concentrations of PE₁-PE₂ were used to study their effects on rat bone marrow cells. The same volume of saline was added to the control groups instead of PE. During the first trial, PE₁ and PE₂ were added to the cultures at day 0. The largest number of AChE+ cells was detected on day 4. The increase in the number of AChE+ cells induced by PE₁ and PE₂ over the control groups was 30% and 108%, respectively (Fig 9) ($P < 0.001$ for both groups). Figure 10 shows the results obtained from the second set of experiments, when PE₃ and PE₄ were added on day 0. The increases in

the number of AChE+ cells over the controls on day 4 were 102% and 40%, respectively ($P < 0.001$ for both groups). The effects of different doses of PE on AChE+ cell numbers on day 4 was compared (Fig 11). This comparison implied that PE₂ (prepared from 675×10^6 platelets/ml) was the optimal concentration, since the largest number of AChE+ cells was detected. Larger amounts of PE were less effective for maintaining maximal numbers of these cells in plasma cultures.

The PDGF, known to be present in PE, was investigated to determine whether it was responsible for the increased number of AChE+ cells in cultures that contained PE. Six and 12 ng PDGF/ml culture medium were added to two separate groups of cultures on day 0 of incubation. The control groups had the same volume of 1.0 M acetic acid adjusted to pH 7.4 with sodium bicarbonate, instead of PDGF. The number of AChE+ cells scored on day 4, in the cultures contained 6 ng and 12 ng PDGF/ml medium, were 23% and 20% higher than the control groups, respectively (Fig 12) ($P < 0.005$ for both groups). Two dosage levels of PDGF were about equally effective in causing an increased number of AChE+ cells.

In order to compare the maximum effects of PE and PDGF, results of two series of experiments were

plotted in Figure 13. It was clear that the total increase in the number of AChE+ cells scored on day 4 was 85% higher in cultures containing PE₂, than in the cultures that contained 6 ng PDGF/ml medium (P < 0.001).

The presence of WBC colonies in the experiments with PE was also quantitated in order to compare their occurrence to that of AChE+ cells. In both sets of PE experiments, the largest number of WBC colonies was scored on day 5. In the first set (PE₁ and PE₂) the difference in the numbers of WBC colonies between the experimental and the control groups was not statistically significant (Table 2). In the second series using PE₃ and PE₄, the number of WBC colonies/clot was lower in both groups than in the control group (Table 3). These differences were highly significant on day 5 (P < 0.005 for both groups). However, the number of WBC colonies in the PE₃ group did not differ significantly from the PE₄ group. The number of WBC/colony in the control groups of both sets sometimes exceeded 64 cells/colony on day 6, but there were never more than 64 cells/colony in all of the groups that received PE.

The mean diameters of megakaryocytic (AChE+) cells were measured in order to determine the effect of different concentrations of PE and PDGF on the size of these cells. On day 3, there were significant increases

in the mean cell diameters of 10% and 14.5% in the cultures receiving PE₁ and PE₂, respectively (Fig 14), when compared to the control groups on day 3 (P<0.05 and P<0.03, respectively). However, the differences between the PE₁ and PE₂ groups was not significant. The results obtained from the second series using PE₃ and PE₄ were shown in Figure 15. Significant increases of 13.8% and 7.4% were noted when the mean diameters of AChE+ cells in the PE₃ and PE₄ groups were compared to the control groups on day 3 (P<0.001 and P<0.005, respectively). The difference between the PE₃ and PE₄ groups again was not significant. The dose dependent effect of PE on the cell size was similar to the results obtained from the counts of the numbers of AChE+ cells. Again, PE₂ was the optimal concentration for producing an increase in the mean cell diameters.

Examination of the cultures in the experimental series that received 6 ng and 12 ng PDGF/ml medium showed no significant differences in the mean diameters of AChE+ cells, when compared with the controls (Table 4).

DISCUSSION

Megakaryocytes have been grown in plasma clot cultures using pokeweed mitogen-stimulated mouse spleen cell conditioned medium (9,11,14). In addition conditioned media have been obtained from 2-mercaptoethanol (5) and phytohemagglutinin (PHA)-stimulated mouse spleen cells (14), a mixture from a leukemia cell line (45), from PHA-stimulated leukocytes (16,19), and from a rat liver cell line (18). Human urinary and sheep erythropoietin have also been successfully used for this purpose (10) (Table 1). Although the target cell(s) and the role of the mitogens in conditioned media production, and the relationship of conditioned media to physiological regulator(s) remain elusive, data were presented here indicating that pokeweed mitogen-stimulated RSCCM could also be used for the stimulation of CFU-M. However, it was essential to produce substantial amounts of conditioned media, since individual lots varied considerably in potency. The reason for this variation has not been explained. The in vitro stimulation of megakaryocyte progenitors by various non-specific conditioned media raised the possibility that these factors might not be of physiological importance. Perhaps they were operating at significantly higher concentrations than would have occurred in vivo,

and a minor degree of hormone receptor cross-reactivity could then have accounted for the stimulation of megakaryocyte growth.

It has been stated that in vitro growth of mouse megakaryocytes depended on the presence of conditioned medium in the cultures (14). It was interesting that megakaryocyte growth occurred in the absence of conditioned medium in this study (Fig 1). An approximate increase of 40% in the number of megakaryocytes relative to day 0 was detected in those cultures that did not have RSCCM. More precise studies would be needed before the relevance of the in vitro finding to the physiological regulation of megakaryocytopoiesis could be regarded as conclusive.

The cyclic growth of megakaryocyte colonies, with peak numbers on days 4 and 8, in the presence of plasma, but not serum, brings about speculations. Studies with ~~agar~~ cultures revealed that the average increase in big cell colony size was due to the appearance between days 5 and 7, of previously unrecognized larger colonies (46). This might have occurred in our cultures. However, precursor cells might have continued to multiply, or perhaps colonies might have resulted from a subset of CFU-M that was slower in cycling status. Furthermore, this slower cycling status might have been due to the

absence of some stimulatory substance(s) in plasma.

Fetal calf, human, bovine, guinea pig and horse sera at varying concentrations ranging from 2% to 30% have been used in semi-solid cultures of megakaryocytes (9,10,11,12,16,17,19,47,48). We have determined that a maximal concentration of 10% rat serum was optimal for plasma clot cultures of rat megakaryocytes in our studies and should be used in future experiments. A medium containing 10% rat serum was shown to be 17% and 28% more effective for support of cell growth and development, than 15% and 20% rat serum, respectively. Various concentrations of rat plasma without any serum were also tested. It was found that 10% rat plasma was more effective than concentrations of 15% or 20% plasma. Thus, it appeared that rat serum and plasma concentrations higher than 10% had an inhibitory effect on megakaryocyte proliferation. Similarly, an inhibitory effect of human serum on the growth of megakaryocyte colonies was reported at low cell concentrations (16). The determination that this inhibitor might be specific for megakaryocytes would require further investigations.

The substitution of fetal calf serum for horse serum resulted, in an earlier study (49), in greater growth of megakaryocytes. This present study also concluded that a 10% concentration of rat serum induced a

22% greater cell proliferation than 20% horse serum. Ten percent horse serum was not tested. However, the greater cell growth, when 10% rat serum was used, implied that cross-species components like serum and plasma might be less compatible to the cultures, than sera or plasma derived from the same species, and might require larger amounts of sera or plasma to be used. The response(s) of cells to foreign proteins present in serum and plasma might also play an important role in the generalized effects of serum and plasma.

Adenosine diphosphate (ADP) is released from platelets during blood coagulation as part of the release reaction (50). Serum is the fluid part of coagulated blood and contains platelet products. Thus, considerably more ADP may be available in serum than in plasma. It was shown that 10 μ M ADP caused spherical megakaryocytes to spread and flatten to several times their normal size (51). The smaller size of AChE+ cells and their oval to round shapes in the plasma-alone study might have been caused by the smaller amount of ADP, or by some other component(s) present in serum but not present in plasma.

A major difference between serum and plasma is the absence of several clotting factors in serum. Therefore, 10% extra plasma was added to the cultures to substitute for the 10% rat serum, in the hope of simplifying the

system. However, the number of megakaryocytes in each clot was 38% greater, when 10% plasma plus 10% serum were used, instead of 20% plasma alone. Since platelets break open during hemostasis (52), the greater stimulation of cell growth caused by plasma plus serum, rather than plasma alone, implied that the presence of stimulatory factor(s) in the serum or of inhibitory factor(s) in the plasma. It was likely that the factor(s) came from the platelets.

The consistency of the concept of inhibition of hematopoietic stem cells by their end products depends on the type and contents of the mature offspring of these cells. This same concept does not also exclude the possibility of a positive feedback mechanism involving factors directly elaborated from the end product of the hematopoietic stem cell. There is at least one clear example of the existence of both positive and negative feedback control systems for granulocyte-macrophage stem cells (colony forming unit-culture, CFU-C) involving a monocyte-derived colony stimulating factor (CSF) and prostaglandin E (PGE) respectively (53). The present study demonstrated that PE and human PDGF significantly increased the numbers and the mean diameters of rat AChE+ cells in vitro.

The effect of hydroxyurea on the cyclic status

of the CFU-M is an open question because of different experimental techniques which resulted in differences in exposure of the cells to toxic levels of the drug (1), and the CFU-M were less sensitive to the drug than were the CFU-C (12). Furthermore, only 7-20% of CFU-M had been shown to be in DNA synthesis (1). Nevertheless, Williams et al (37) have reported that mouse bone marrow CFU-M were not put out of cell cycle by platelets or PE as compared to hydroxyurea treatments in vitro and in vivo. Their results implied that the slow cycling CFU-M compartment cells were not responsive to PE, but did not eliminate the possible responsiveness of small AChE+ or subsequent cell populations to PE and PDGF.

The increase in megakaryocytes as a function of time in culture is a complex function balancing megakaryocyte loss through platelet formation and cell death against new megakaryocyte production from progenitor cells. It has not been easy at this moment to delineate how and where PE influenced the production of new megakaryocytes or inhibited the cell loss through cell death or differentiation. Either of which could lead to a net increase in megakaryocytes/clot. However, it has been previously suggested that the numbers of megakaryocytes and their colonies were likely to be increased by factors that affected endomitosis and cytoplasmic maturation of megakaryocytes (37). A number of these factors might exist in

PE; one of the best known was PDGF. All of them certainly deserve further investigation.

Studies with acute thrombocytopenia induced by platelet antiserum (54) and cyclophosphamide (55) indicated that changes in CFU-M and CFU-C might have occurred in parallel fashion. Therefore, the number of WBC colonies was quantitated in these studies. Previous investigators concluded that PGE inhibited the growth of WBC colonies in vitro (53). Since the synthesis of PGE by platelets was well documented (56), the decrease in the number of WBC/colony and WBC colonies/clot with the higher concentrations of PE in the medium could be explained.

Odell et al (2) demonstrated that the size of megakaryocytes was proportional to their ploidy. Although the ploidy of the cells in this study was not examined, the increase in the mean cell diameters implied a dose dependent increase in cell ploidy with PE in the medium. The nature of the substance(s) and the type of the cells affected are not clear at the present time. However, the relative increase in the cell size for 3 days suggested that the substance(s) present in PE did not act on CFU-M but rather on the successive megakaryocytic generations, as suggested previously (33,37). Otherwise, the increase in the mean cell diameters would have been continuously

detected after day 3, since most mature megakaryocytes in colonies increased in area from days 4 to 7 of culture (11). In these experiments, the relatively small increase in the cell size could be explained, if there were a reciprocal relationship between cell size and the number of AChE+ cells; increases in cell number decrease the size, or vice versa. More direct studies are necessary in this regard.

The present study with PDGF indicated that a commercial preparation of purified human PDGF markedly increased the numbers of megakaryocytes in plasma clot cultures. Although platelets have a rudimentary biosynthetic apparatus, recent findings suggested that megakaryocytes might be the site of synthesis of PDGF (38). Primary Myelofibrosis (PMF) is a chronic myeloproliferative disorder characterized by an abnormal accumulation of collagen in bone marrow and an excessive proliferation of marrow fibroblasts in bone marrow and in extramedullary sites. The pathophysiological mechanisms leading to marrow fibrosis are unknown, but growth promoting activity of PDGF on human marrow fibroblasts has been well characterized (38). Platelet kinetic studies have demonstrated that ineffective thrombopoiesis occurred in PMF, with a highly increased death rate of megakaryocytes (57). The ineffective thrombo-

poiesis due to highly increased death rate of megakaryocytes in PMF might possibly have been due to the presence of PDGF that was elaborated from the dead megakaryocytes in the bone marrow.

Recently it has been reported in 3T3 cells that PDGF acts in G_0 phase, rendering cells competent to respond to other serum growth factors, such as somatomedins (58). Also at the onset of G_1 phase immediately after mitosis, PDGF prevented cells from entering the G_0 phase (59). However, the question of whether the effect of PDGF on rat bone marrow megakaryocytes is similar to that of 3T3, or some more complex phenomenon is involved, still remains unresolved.

The total percentage increase in the number of megakaryocytes/clot was higher in the PE experiments than in the PDGF experiments. This difference indicated possible effects of (an)other platelet factor(s), in addition to PDGF, in PE. These include ADP, epinephrine, cations, platelet factors 1 through 10, cyclooxygenase, lipids, thromboxane A_2 and prostaglandins E_1 , E_2 and F_2 alpha (60). Kurland et al (53), in studies of human granulopoiesis, have shown that PGE inhibited CFU-C growth and PGF_2 alpha enhanced murine CFU-C growth (61). Recently it has been demonstrated that nine PGs added to human bone marrow cell cultures

increased the number of erythroid colonies up to 95%, in the presence of erythropoietin, and also that PGF_2 alpha consistently inhibited erythropoiesis over a wide range of concentrations (62). These results clearly indicated that PGs modulate granulopoiesis and erythropoiesis, and might also be involved in the control of megakaryocytopoiesis. More precise and extensive research is anticipated in this area.

SUMMARY

An improved plasma clot culture system was developed for the growth of rat megakaryocytic cells. These cells were characterized histochemically by an acetylcholinesterase positive (AChE+) staining reaction. The conditioned medium, obtained from pokeweed mitogen-stimulated rat spleen cells, induced megakaryocyte colony formation and full maturation of megakaryocytes to cytoplasmic fragmentation. Ten percent rat serum was more effective than 20% horse serum in supporting cell growth. Greater stimulation of cell growth was provided when both serum and plasma were added to the culture medium, than when plasma was added alone. The use of a single species as the donor of bone marrow cells, spleen cells conditioned medium, plasma, and serum provided a less complex culture medium for the study of megakaryocyte development.

Rat platelet extract and human PDGF were assayed in this culture system, in order to study the ability of these materials to modify the proliferation and/or maturation of megakaryocytic cells. Extracts prepared from 675×10^6 platelets or 6 ng PDGF/ml caused maximum increases over the controls of 108% or 23%, respectively, in the number of AChE+ cells. Higher concentrations of

platelet extracts were found to be less effective in stimulating the maturation of megakaryocytic cells. It was also found that this same dose of PE caused an increase of 14.5% in the mean diameters of AChE+ cells. PDGF had no effect on cell size. The PE also caused reduction in the number of WBC colonies in one series of experiments. It was not clear how and where PE or PDGF stimulated the production of new megakaryocytic cells, or inhibited the loss of these cells by cell death or by differentiation into platelets. However, the increase in the numbers and diameters of AChE+ cells induced by PE implied that substance(s) released by platelets might play a physiological role in the control of megakaryocytopoiesis.

Figure 1. The response of rat bone marrow cells to different lots of rat spleen cells conditioned medium (RSCCM). The control medium contained 10% isotonic saline instead of RSCCM. The number of megakaryocytic cells, scored as acetylcholinesterase positive (AChE+) cells/ 3×10^5 nucleated bone marrow cells, was significantly greater than the controls when RSCCM₃ ($P < 0.001$) and RSCCM₂ ($P < 0.005$) were used, but was not significant when RSCCM₁ was used. Each point was the average of 3 to 4 cultures/day combined from 2 to 5 different experiments. The standard errors of the mean were shown by vertical lines in this and all the following figures.




Figure 2. The effect of culture media containing 10%, 15% or 20% (v:v) rat serum on rat megakaryocytic (AChE+) cell growth. The cultures containing 10% and 15% serum also contained 10% and 5% isotonic saline, respectively, to compensate for the 20% serum. The results of the groups containing 10% and 15% serum were combined from three different experiments. The data from the 20% serum group was the average of two different experiments ($P < 0.001$ for both 10% vs. 15% and 10% vs. 20% serum groups).




Figure 3. The effect of culture media containing 10%, 15% or 20% rat serum on the number of megakaryocytic (AChE+) cell colonies. This was from the same experiments as in Figure 2. The number of colonies was significantly greater on day 4, when 10% rat serum was used, than when 15% or 20% rat serum was used ($P < 0.1$ and 0.05 respectively).




Figure 4. A comparison of 20% horse serum and 10% rat serum on the growth of megakaryocytic (AChE+) rat bone marrow cells. Ten percent rat serum resulted in a 22% greater increase in cell numbers on day 4 than 20% horse serum ($P < 0.01$). The results were averaged from two different experiments.




Figure 5. The effects of different concentrations of rat plasma in the medium on the growth of megakaryocytic (AChE+) cells. Serum was not added to the medium. The differences between 10% and 15% plasma, and 10% and 20% plasma on day 3 were significant ($P < 0.02$ and $P < 0.01$, respectively). The results were combined from two to three different experiments.




Figure 6. The number of megakaryocytic (AChE+) cell colonies from the same experiments as Figure 5 were shown. The number of cell colonies were maximum at days 4 and 8 ($P < 0.02$ for 10% vs. 15% plasma groups and $P < 0.005$ for 10% vs. 20% plasma groups).




Figure 7. The number of white blood cell colonies from the same experiments as Figure 5 were shown ($P < 0.01$ for 10% vs. 15% plasma groups and $P < 0.001$ for 10% vs. 20% plasma groups).




Figure 8. The effects of the 10% rat serum from Figure 2 and the 10% rat plasma from Figure 5 on stimulation of the growth of megakaryocytic (AChE+) cells were compared statistically ($P < 0.001$ for serum groups at day 4 and plasma groups at day 3).




Figure 9. The effect of extracts prepared from 450×10^6 (PE_1) and 675×10^6 (PE_2) platelets/ml saline on nucleated bone marrow cells. The control medium contained the same volume of isotonic saline instead of PE. Each plasma clot was 0.3 ml of culture medium with 3×10^5 nucleated bone marrow cells. The results represented the average number of megakaryocytic (AChE+) cells from two (with PE_1) and three (with PE_2) different experiments. The number of AChE+ cells were increased 30% with PE_1 in the medium ($P < 0.001$) and 108% with PE_2 in the medium ($P < 0.001$) over the control groups at day 4.




Figure 10. The response of 3×10^3 nucleated bone marrow cells/0.3 ml clot to extracts prepared from 900×10^6 (PE_3) and 1800×10^6 (PE_4) platelets/ml isotonic saline. The control medium contained the same volume of saline instead of PE. The results were the mean number of megakaryocytic (AChE+) cells from two (with PE_4) and three (with PE_3) different experiments. Three to four plasma clots were examined on each day of incubation. The increases in the number of detectable AChE+ cells at day 4, over the controls, were 102% with PE_3 in the medium ($P < 0.001$) and 40% with PE_4 in the medium ($P < 0.001$).




Figure 11. A comparison of the effect of different doses of platelet extracts on the number of AChE+ cells scored at day 4. The data were obtained from the same experiments presented in Figures 9 and 10.




Figure 12. The effects of 6 ng and 12 ng platelet-derived growth factor/ml medium on nucleated bone marrow cells. The control medium contained the same volume of 1.0 M acetic acid neutralized with sodium bicarbonate. The results represented the average number of megakaryocytic (AChE+) cells from three different experiments. The increases in the detectable cells were 23% with 6 ng PDGF/ml and 20% with 12 ng PDGF/ml (P < 0.005 for both groups), when compared to the control group at day 4.




Figure 13. The comparison of the responses of megakaryocytic (AChE+) cells to the extracts prepared from 675×10^6 platelets/ml and 6 ng PDGF/ml scored at day 4. The data were obtained from the same experiments presented in Figures 9 and 12.




Figure 14. The changes in the mean diameters of megakaryocytic (AChE+) cells in response to 450×10^6 (PE₁) and 675×10^6 (PE₂) platelet extracts/ml saline on successive days. The results were obtained from the same clots as in Figure 9. One hundred to 140 cells of each group were measured every day. Ten percent and 14.5% increases in the cell size with the presence of PE₁ and PE₂, respectively, were calculated over the control groups at day 3 ($P < 0.05$ and $P < 0.03$, respectively). The differences between PE₁ and PE₂ was not significant.




Figure 15. The effects of 900×10^6 and 1800×10^6 PE/ml medium on the mean diameters of megakaryocytic (AChE+) cells in plasma clot cultures at days 0 to 7. The results came from the same experiments as in Figure 10. One hundred to 140 cells of each group were measured every day. The increases in the mean cell diameters were 13.8% with PE₃ in the medium and 7.4% with PE₄ in the medium, when compared to the control groups at day 3 ($P < 0.001$ and $P < 0.005$, respectively).




Table 1. Culture conditions for megakaryocyte growth.

<u>PLASMA CLOT</u>				
<u>Cell source</u>	<u>Culture medium</u>	<u>Serum</u>	<u>Stimulators</u>	<u>Reference</u>
Mouse-BM	L-15	20% HS	MS-PWM	9
Mouse-BM	NCTC-109	20% FCS	Human and sheep-Ep	10
Mouse-BM	NCTC-109	15% HS	MS-PWM	11
Human-BM	Alpha medium	20% human	Human-Ep	12
Mouse-BM	L-15	20% FCS	TSF	15
Human-BM	Alpha medium	2.5-20% human	Leukocyte-PHA	16
Mouse-BM	NCTC-109	20% FCS	Human urine	17
<u>AGAR</u>				
Rat-BM	Dulbecco's	20% FCS	Rat liver-CM	18
Mouse-BM	Eagle's	15% FCS	MS- 2-ME	5
Mouse-BM	McCoy's 5A	15% FCS	WEHI-3 + BM	6
Mouse-BM	Eagle's	20% FCS	MS-PWM	7
Mouse-spleen	"	"	"	"
Mouse-blood	"	"	"	"
<u>METHYLCELLULOSE</u>				
Human-BM	Alpha medium	30% FCS	Leukocyte-PHA	19

BM= Bone Marrow
 FCS= Fetal Calf Serum
 MS= Mouse Spleen cells
 Ep= Erythropoietin
 PWM= Pokeweed Mitogen

CM= Conditioned Medium
 HS= Horse Serum
 2-ME= 2-Mercaptoethanol
 PHA= Phytohemagglutinin
 TSF= Thrombocytopoiesis-Stimulating Factor.

Table 2. The effect of platelet extracts on white blood cell colonies/culture.

<u>Days in Culture</u>	<u>Number of white blood cell colonies/clot</u>		
	<u>Control</u>	<u>450 x 10⁶ PE/ml</u>	<u>675 x 10⁶ PE/ml</u>
3	14.7 ± 0.6	17.0 ± 0.6	16.7 ± 1.5
4	21.7 ± 1.7	25.2 ± 2.2	26.0 ± 2.1
5	39.2 ± 3.7	41.6 ± 4.0	42.0 ± 2.6
6	26.0 ± 1.4	23.5 ± 2.1	24.5 ± 0.7
7	20.3 ± 2.3	22.3 ± 1.5	18.3 ± 2.5
8	15.5 ± 0.7	16.5 ± 0.7	12.5 ± 0.7

The data were obtained from the same experiments as in Figure 9. Mean ± SEM of 3 to 4 cultures from each of 2 to 3 experiments.

Table 3. The effect of platelet extracts on white blood cell colonies/culture.

<u>Days in Culture</u>	<u>Number of white blood cell colonies/clot</u>		
	<u>Control</u>	<u>900 x 10⁶ PE/ml</u>	<u>1800 x 10⁶ PE/ml</u>
2	11.3 ± 1.5	11.0 ± 1.0	10.3 ± 1.1
3	18.0 ± 2.1	17.7 ± 2.7	18.0 ± 1.9
4	30.2 ± 1.2	28.2 ± 2.0	26.2 ± 1.7
5	42.7 ± 1.7	36.2 ± 1.7	34.7 ± 1.7
6	33.0 ± 1.4	29.5 ± 2.1	28.0 ± 1.4
7	23.0 ± 1.4	21.0 ± 0.6	19.5 ± 0.7

The data were obtained from the same experiment as in Figure 10. Mean ± SEM of 3 to 4 cultures from each of 2 to 3 experiments.

Table 4. The effect of platelet-derived growth factor on the mean size of megakaryocytic cells.

<u>Days in Culture</u>	<u>Mean size of megakaryocytic cells (um)</u>		
	<u>Control</u>	<u>6 ng PDGF/ml</u>	<u>12 ng PDGF/ml</u>
0	23.9 ± 0.8	23.5 ± 0.8	23.2 ± 0.8
1	22.8 ± 0.3	22.7 ± 0.3	22.9 ± 0.7
2	N.T	N.T	N.T
3	23.0 ± 0.8	22.8 ± 0.8	23.2 ± 0.7
4	21.5 ± 0.6	21.4 ± 0.7	21.3 ± 0.7
5	20.6 ± 0.7	21.0 ± 0.7	20.6 ± 0.6
6	20.9 ± 0.7	20.0 ± 0.7	19.9 ± 0.7
7	20.0 ± 0.6	19.9 ± 0.6	19.5 ± 0.6
8	19.2 ± 0.6	19.8 ± 0.6	19.0 ± 0.6
9	17.4 ± 0.6	16.7 ± 0.5	16.8 ± 0.5

The data were obtained from the same experiments as in Figure 12. Mean ± SEM of 3-4 cultures from each of three experiments. One hundred to 140 cells of each group were measured every day. N.T. = Not tested.

BIBLIOGRAPHY

1. Ebbe S. Megakaryocytopoiesis in vivo. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocytes Biology andPrecursors: in vitro Cloning and Cellular Properties. New York:Elsevier/North-Holland, 1981;1-13.
2. Odell TT Jr., Jackson CW, Friday TJ. Megakaryocytopoiesis in rats with special reference to ploidy. Blood 1970;35:775-782.
3. Paulus JM, Bury J, Grosdent JC. Control of platelet territory development in megakaryocytes. Blood Cells 1979;5:59-68.
4. Tavassoli M. Megakaryocyte-platelet axis and the process of platelet formation and release. Blood 1980;55:537-545.
5. Metcalf D, MacDonald HR, Odartchenko N, Sordat B. Growth of mouse megakaryocyte colonies in vitro. Proc Nat Acad Sci USA 1975;72:1744-1748.
6. Williams NT, Jackson H, Sheridan APC, Murphy MJ Jr., Elste A, Moore MS. Regulation of megakaryocytopoiesis in long term murine bone marrow cultures. Blood 1978;51:245-255.
7. Burstein SA, Adamson JW, Thorning D, Harker LA. Characteristics of murine megakaryocytic colonies in vitro. Blood 1979;54:169-179.

8. Nakeff A, Dicke KA, van Noord MJ. Megakaryocytes in agar cultures of mouse bone marrow. *Ser Haematol* 1975;3:1-12.
9. Nakeff A, Daniels-McQueen S. In vitro colony assay for a new class of megakaryocyte precursor:CFU-II. *Proc Soc Exp Biol Med* 1976;151:587-590.
10. McLeod LD, Shreeve MM, Axelrad AA. Introduction of megakaryocyte colonies with platelet formation in vitro. *Nature* 1976;216:492-494.
11. Mizoguchi H, Kubota Y, Kiura Y, Takaku R. An improved plasma culture system for production of megakaryocyte colonies in vitro. *Exp Hematol* 1979;7:345-351.
12. Vainchenker W, Bouquet J, Guichard J, Breton-Gorius J. Megakaryocyte colony formation from human bone marrow precursors. *Blood* 1979;54:940-945.
13. Levine RF, Fedorko ME. Isolation of intact megakaryocytes from guinea pig marrow, successful harvest made possible with inhibition of platelet aggregation: enrichment achieved with a two step separation technique. *J Cell Biol* 1976;69:159-169.
14. Nakeff A. Examination of culture conditions for optimizing the growth of megakaryocyte colonies. In: Evatt BL, Levine RF, Williams NT, eds. *Megakaryocyte Biology and Precursors: in vitro Cloning and*

- Cellular Properties. New York:Elsevier/North-Holland, 1981;111-125.
15. Kalmaz GD, McDonald TP. The effect of thrombopoietin on megakaryocytopoiesis of mouse bone marrow cells in vitro. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York:Elsevier/North-Holland, 1981;77-86.
 16. Vainchenker W, Breton-Gorius J, Chapman J. Induction of human megakaryocyte colonies in vitro and ultra-structural aspects of their maturation. In:Evatt, BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York:Elsevier/North-Holland 1981;139-60.
 17. Dukes PP, Gompert E, Izadi P. Modulation of megakaryocyte colony formation by protein fractions from the urine of normal and anemic individual. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York, Elsevier/North-Holland, 1981: 87-96.
 18. Penington DG. Megakaryocyte colony culture using a liver cell conditioned medium. Blood Cells 1979;5: 13-23.
 19. Messner HA, Fauser AA. Megakaryocytes in human mixed

- hematopoietic colonies. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York, Elsevier/North-Holland, 1981:160-171.
20. Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York:Elsevier/Noth-Holland, 1981;16-334.
 21. Harker LA. Kinetics of thrombopoiesis. J Clin Invest 1968;47:458-465.
 22. Ebbe S. Megakaryocytopoiesis. In:Gordon SA, ed. Regulation of Hematopoiesis. New York:Appleton-Century Crofts, Vol 2, 1970:1587-1610.
 23. Cooper GW, Cooper B, Ossias AL, Zanjani ED. A hypertransfused mouse assay for thrombopoietic factors. Blood 1973;42:423-428.
 24. Burstein SA, Adamson JW, Erb SK, Harker LA. Regulation of murine megakaryocytopoiesis. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York:Elsevier/Noth-Holland, 1981:128-38.
 25. Williams NT, Eger RR, Jackson HM, Nelson DJ. Two-Factor requirement for murine megakaryocyte colony formation. J Cell Physiol 1982;110:101-104.
 26. Levin J. Murine megakaryocytopoiesis in vitro:Ana-

- lysis of culture systems used for the study of megakaryocyte colony-forming cells and of the characteristics of megakaryocyte colonies. *Blood* 1983;61:617-623.
27. Paulus JM, Maigne J, Keyhani E. Mouse megakaryocytes secrete acetylcholinesterase. *Blood* 1981;58:1100-06.
 28. Craddock CG Jr., Adams WS, Perry S, Lawrence JS. The dynamics of platelet production as studied by a depletion technique in normal and irradiated dogs. *J Lab Clin Med* 1955;45:906-919.
 29. Cronkite EP. Regulation of platelet production. In: *Homeostatic Mechanisms. Brookhaven Symposia in Biology* 1957;10:96-07
 30. Evatt BL, Levin J, Algazy KM. Partial purification of thrombopoietin from the plasma of thrombopoietic rabbits. *Blood* 1979;54:377-388.
 31. McDonald TP, Clift R, Large RD, Tribby II, Barlow GH. Thrombopoietin production by human embryonic kidney cells in culture. *J Lab Clin Med.* 1975;85:59-66.
 32. Lichtman MA, Chamberlain JK, Simon W, Santillo PA. Parasinusoidal location of megakaryocytes in the marrow: A determination of platelet release. *Am J Hematol* 1978;4:303-308.
 33. Williams NT, Jackson H. Regulation of the production of murine megakaryocyte progenitor cells by cell

- cycle. Blood 1978;52:163-70.
34. Broxmeyer HE, Moore MA, Ralph P. Cell-free granulocyte inhibiting activity derived from human polymorphonuclear neutrophils. Exp Hematol 1977;5:87-92.
 35. Lord BI, Shah GP, Lajtha LG. The effects of red blood cells extracts on the proliferation of erythrocyte precursor cells in vitro. Cell Tissue Kinet 1977;10:215-222.
 36. Lord BI, Cercek L, Cercek B, Shah GP, Dexter TM, Lajtha LG. Inhibitors of hematopoietic cell proliferation? Specificity of action within haematopoietic system. Br J Cancer 1977;29:168-172.
 37. Williams NT, McDonald TP, Rabellino EM. Maturation and regulation of megakaryocytopoiesis. Blood 1979;5:43-55.
 38. Castro-Malaspina H, Rabellino EM, Yen A, Levene R, Nachman RL, Moore MAS. Human megakaryocyte derived growth factor(s). Studied in 3T3 cells and bone marrow fibroblasts. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York: Elsevier/North-Holland, 1981:329-334.
 39. Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Sher CD. Platelet-granules contain a growth factor for fibroblasts. Blood 1979;53:1043-52.

40. Antoniades HN, Hunkapiller MW. Human platelet-derived growth factor: Amino-terminal amino acid sequence. Science 1983;20:963-965.
41. Ross R, Vogel A. The platelet-derived growth factor. Cell 1978;14:203-210.
42. Goldberg J, Phalen E, Howard D, Ebbe S, Stohlman F Jr. Thrombocytotic suppression of megakaryocyte production from stem cells. Blood 1977;49:59-63.
43. Krizsa F, Keleman E, Cserhati I, Lajtha LG. Specific thrombopoietic inhibition by syngeneic platelet homogenates. Biomedicine 1977;27:145-157.
44. Karnovsky MJ, Roots L. A "direct-coloring" thiocholine method for cholinesterase. J Histochem Cytochem 1964;12:219-221.
45. Metcalf D, Johnson GR. Production by spleen and lymph node cells of conditioned medium with erythroid and other hematopoietic colony stimulating activity. J Cell Physiol 1978;96:31-42.
46. Lieschke GJ. Kinetics of the formation of pure and heterogeneous megakaryocyte colonies by megakaryocyte progenitor cells in vitro. Exp Hematol 1982;10:73-89.
47. Groopman JE, Haudenschild CH, Goldwasser E, Stiles CD, Sher CD. Study of in vitro megakaryocytopoiesis in a permanent candidate rat megakaryocyte line. In: Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biolo-

- gy and Precursors: in vitro Cloning and Cellular Properties. New York:Elsevier/North-Holland, 1981;305-12.
48. Kellar KL, Evatt BL, McGrath CR, Ramsey RB. Stimulation of DNA synthesis in megakaryocytes by thrombopoietin in vitro. In:Evatt BL, Levin RF, Williams, NT, eds. Megakaryocyte Biology and Precursors: in vitro Cloning and Cellular Properties. New York:Elsevier/North-Holland, 1981:21-38.
49. Nakeff A. Colony forming unit megakaryocytes (CFU-M), its use in elucidating the kinetics and humoral control of megakaryocytic committed progenitor cell compartment. In:Baum SJ, Ledney GD, eds. Experimental Hematology Today. New York:Springer-Verlag, 1977:11-23.
50. Grette K. The mechanism of thrombin-catalyzed hemostatic reaction in platelets. Acta Physiol Scand 1962;195-93.
51. Leven RM, Machmias VT. Response of cultured megakaryocytes to adenosine diphosphate. In:Evatt BL, Levin RF, Williams NT, eds. Megakaryocyte Biology and Precursors:in vitro Cloning and Cellular Properties. New York:Elsevier/Norht-Holland, 1981:261-270.
52. Weiss JM. Platelet physiology and abnormalities of platelet function. New England J Med 1975;293:531-41.
53. Kurland JI, Bockman RS, Broxmeyer HE, Moore MA. Limitation of excessive myelopoiesis by the intrinsic mo-

- dulation of macrophage-derived prostaglandin E.
Science 1978;199:552-555.
54. Levin J, Levin FC, Metcalf D, Penington DG. The effects of acute thrombocytopenia upon megakaryocyte-CFU and granulocyte-macrophage-CFU in the bone marrow and spleen of mice:with studies of ploidy distribution in megakaryocyte colonies. In:Evatt BL, Levine RF, Williams NT, eds. Megakaryocyte Biology and Precursors:in vitro Cloning and Cellular Properties. New York:Elsevier/North-Holland, 1981;180-90.
55. Yeager AM, Levin CF, Levin J. Effects of cyclophosphamide on bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels. J Cell Physiol 1982;112:222-228.
56. McGiff JC. Prostaglandins, prostacyclin, and thromboxanes. Ann Rev Pharmacol Toxicol 1981;21:479-509.
57. Harker LH, Finch CA. Thrombokinetis in man. J Clin Invest 1969;48:963-74.
58. Stiles CD, Capone GT, Sher CD, Antoniades NH, Van Wyck JJ, Pledger WJ. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 1979;76:1279-86.
59. Yen AG, Riddle VGH. Plasma and platelets associated factor act in G_1 to maintain proliferation and to stabilize arrested cells in a viable quiescent state.

- A temporal map of control points in the G₁ phase.
Exp Cell Res 1979;120:349-357.
60. Caen JP, Cronberg S, Kubisz P. Platelet:Physiology and Pathology. New York, Stratton 1977;15-23.
61. Kurland JI, Hadden JW, Moore MAS. Role of cyclic nucleotides in the proliferation of committed granulocyte-macrophage progenitor cells. Cancer Res 1977; 37:4534-4541.
62. Chan HE, Saunders EF, Freedman MH. Modulation of human hematopoiesis by prostaglandins and lithium. J Lab Clin Med 1980;95:125-132.